Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular and Ocular Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTPRB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPRB ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed for native glycosylation. |
View PTPRB Products |
| Gene Delivery | PTPRB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View PTPRB Products |
| Benchmark Ab | Anti-PTPRB Recombinant Antibody Recombinant positive control derived from benchmark clinical/preclinical sequences. |
View PTPRB Products |
| Validator | PTPRB siRNA Set Target-specific knockdown pool for functional assay validation. |
View PTPRB Products |
| Related Target A | TEK (TIE2) Primary substrate of PTPRB. Dephosphorylation of TEK by PTPRB destabilizes vasculature. |
View TEK Products |
| Related Target B | ANGPT2 (Angiopoietin-2) Synergistic pathway regulator in vascular leakage and neovascularization. |
View ANGPT2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Large ECD | HEK293 mammalian expression ensures correct folding of the 17 fibronectin type III-like domains. |
| Subfamily Off-Target Screening | Homolog panel proteins (PTPRJ, PTPRC) strictly verified by mass spectrometry for selectivity assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live PTPRB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTPRB therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted monoclonal and bispecific antibodies. PTPRB (also known as VE-PTP) acts as a critical negative regulator of the Tie2 receptor tyrosine kinase in vascular endothelial cells. By inhibiting PTPRB, therapeutics aim to restore Tie2 activation, thereby stabilizing blood vessels and reducing vascular permeability. As first-generation systemic therapies reach the clinic, the next wave of R&D is targeting localized ocular delivery and bispecific platforms to minimize systemic cardiovascular side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Aerpio Pharmaceuticals, Academic Institutions | Diabetic Macular Edema (DME), Diabetic Retinopathy | Binding Affinity & Blocking Assay (Need high-purity ECD-Fc) |
| Bispecific Antibody | Ocular Biopharma Developers | Neovascular Age-Related Macular Degeneration (nAMD) | Simultaneous binding assays (Need PTPRB and VEGFA/ANGPT2 proteins) |
| Small Molecule | Preclinical Stage Biotech | Solid Tumors (Anti-angiogenesis), Vascular Leak | Selectivity Assay (Need Mutant vs WT Catalytic Domain Proteins) |